Novo Nordisk Reduces Ozempic, Wegovy Prices In India Amid Generic Competition

In India, Novo Nordisk has lowered the cost of its blockbuster medications, Ozempic and Wegovy, in response to cheaper substitutes, which are becoming more competitive.

The price cuts come after the expiry of the patent for semaglutide, the key ingredient in both drugs, on 20 March. This has opened the market to multiple domestic pharmaceutical companies.

In response, the firm lowered the price as much as 36% on Ozempic and 48% on Wegovy to retain its market share as generic equivalents enter the market.

How Are Prices Changing And What Is Driving The Cut?

After the revision, the initial dose of 0.25 mg now costs ₹1,415 per weekly injection, compared to ₹2,200 and ₹2,712 in the past.

Prices of Ozempic and Wegovy have been cut down on average by 23.8% and 27%, respectively, at different dosage levels.

Higher doses have also seen notable cuts. The 1 mg dose is now priced at ₹2,275 after reductions of 18.5% and 34.2%, while Wegovy’s 0.5 mg dose has been reduced by over 40%.

These changes come as several Indian drugmakers, including Dr Reddy’s Laboratories, Zydus, Sun Pharma, have launched competing versions at significantly lower prices, in some cases up to 70% cheaper.

What Does This Mean For Market Competition?

The entry of generics is expected to change India’s diabetes and weight-loss drug market.

Alongside Novo Nordisk, companies like Eli Lilly are also competing in this space. Eli Lilly’s drug Mounjaro has already emerged as a leading product by sales value in a short period.

As many different variations are offered at the moment, the prices and the availability are bound to form one of the main differentiation aspects of the market.

Also Read - Stock Market Update 1 April: Sensex, Nifty Rise Over 2.5% After Two-Day Losses

What Does This Mean For Investors?

To investors, the declining prices indicate that there is rising competitive pressure in a high-growth segment after the patent has expired.

While a price decline could squeeze short-term margins, higher volumes and greater accessibility would likely stimulate demand.

Shareholders would need to monitor how firms strike a balance between pricing and market share within the competitive industry.

Sources:

Reuters

The Economic Times